KRAS is frequently mutated in human cancers1 and is a driver of neoplasias in the lung, pancreas, colon and biliary tract2, 3, 4, 5, where tumour maintenance is highly dependent on continued oncogenic KRAS expression6, 7. This evidence concerns the gene KRAS and neoplasm.